Business - Briefly   

Final USFDA nod for Orchid's Cefprozil tablets

CHENNAI: Orchid Chemicals and Pharmaceuticals on Tuesday announced that it has received formal approval from the USFDA for its ANDA (Abbreviated New Drug Application) for Cefprozil Tablets USP, 250 mg and 500 mg. Orchid will launch the product exclusively through Par Pharmaceuticals immediately upon the expiry of the patent on December 23, K. Raghavendra Rao, Managing Director, Orchid Chemicals, said. This is the eighth cephalosporin ANDA approval that Orchid has received.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Prioritise domestic oil find: Ministry
ICMR partners MSD
DBT seeks Rs. 1,000 cr. package for biotech
Spice mobile phones in TN
ONGC-CNPC win bid for Syrian oilfields
Small paper units moot alternative to TSDF
SIB extends core banking facility to rural branches
Coir Board asks small producers to drop proposal for strike
APK proposes suspension of minimum wage revision
Emirates to focus more on Kerala
Bharat Overseas Bank suspends 4 managers
HCL consolidates bottomline
140 p.c. final from MRF
SMPIL hearing posted to Dec. 22
Sensex dips on profit booking
Exchange rates
Bullion rates
NTPC moves court against RIL
Reliance finds oil in KG basin
Pfizer launches Viagra in India
Rupee drops 21 paise
Mastek launches new IT solution for insurance cos.
Kisan card from HDFC Bank
Bajaj Allianz launches four new products
Final USFDA nod for Orchid's Cefprozil tablets
Fidelity offers tax advantage fund
Karur Vysya Bank selects Odyssey Snorkel-TX
Bajaj Auto unveils 112cc Discover
Kenexa figures in Software 500

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu